This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asiedu, C. Articles by Kraft, A. S. Search for Related Content PubMed PubMed Citation Articles by Asiedu, C. Articles by Kraft, A. S.

Inhibition of Leukemic Cell Growth by the Protein Kinase C Activator Bryostatin 1 Correlates with the Dephosphorylation of Cyclin-dependent Kinase 2¹

Division of Hematology/Oncology, University of Alabama, Birmingham, Alabama 35294 [C. A., J. B., A. S. K.] and Medical Oncology, Seattle VA Medical Center, University of Washington, Seattle, Washington 98108 [M. L.]

Bryostatin 1 is a natural antineoplastic agent that activates protein kinase C. Treatment of U937 human leukemic cells with bryostatin 1 caused a 60% reduction in cell growth, whereas another protein kinase C activator, phorbol myristate acetate (PMA), completely inhibited U937 cell growth. Both bryostatin 1 and PMA induced inhibition of cyclindependent kinase 2 (cdk2) activity. The first phase of cdk2 inhibition correlated with the transient induction of p21, a known inhibitor of cdk2. In contrast, the second phase of cdk2 inhibition correlated with the dephosphorylation of cdk2 on threonine-160, which must be phosphorylated for cdk2 activity. The level of growth inhibition induced by these two compounds correlated with the degree of cdk2 dephosphorylation as follows: bryostatin 1, 60%; PMA, 100%.

¹ This work was supported by NIH CA 42533 and ACS grant DHP 83 to ASK, CA45672 and a grant from the Veterans Administration Research Program to ML, and ACS grant IRG-66-32 to JB.

² To whom requests for reprints should be addressed, at Division of Hematology/Oncology, University of Alabama/Birmingham, 558T Lurleen B. Wallace Tumor Institute, 1824 Sixth Avenue South, Birmingham, AL 35294-3300.

Received 6/27/95. Accepted 7/20/95.

This article has been cited by other articles:

				G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]

				S. Wang, Z. Wang, and S. Grant Bryostatin 1 and UCN-01 Potentiate 1-beta -D-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms Mol. Pharmacol., January 1, 2003; 63(1): 232 - 242. [Abstract] [Full Text] [PDF]

				R. E. Curiel, C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado Bryostatin-1 and IL-2 Synergize to Induce IFN-{gamma} Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy J. Immunol., November 1, 2001; 167(9): 4828 - 4837. [Abstract] [Full Text] [PDF]

				M. A. Shah and G. K. Schwartz Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2168 - 2181. [Abstract] [Full Text] [PDF]

				J. A. Koutcher, M. Motwani, K. L. Zakian, X.-K. Li, C. Matei, J. P. Dyke, D. Ballon, H. H. Yoo, and G. K. Schwartz The in Vivo Effect of Bryostatin-1 on Paclitaxel-induced Tumor Growth, Mitotic Entry, and Blood Flow Clin. Cancer Res., April 1, 2000; 6(4): 1498 - 1507. [Abstract] [Full Text]

				R. van Gijn, X. Zuidema, A. Bult, and J. H. Beijnen Protein kinase C as a target for new anti-cancer agents Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 166 - 178. [Abstract] [PDF]

				A. Kubo, K. Nakagawa, R. K. Varma, N. K. Conrad, J. Q. Cheng, W.-C. Lee, J. R. Testa, B. E. Johnson, F. J. Kaye, and M. J. Kelley The p16 Status of Tumor Cell Lines Identifies Small Molecule Inhibitors Specific for Cyclin-dependent Kinase 4 Clin. Cancer Res., December 1, 1999; 5(12): 4279 - 4286. [Abstract] [Full Text] [PDF]

				T. Taniguchi, H. Endo, N. Chikatsu, K. Uchimaru, S. Asano, T. Fujita, T. Nakahata, and T. Motokura Expression of p21Cip1/Waf1/Sdi1 and p27Kip1 Cyclin-Dependent Kinase Inhibitors During Human Hematopoiesis Blood, June 15, 1999; 93(12): 4167 - 4178. [Abstract] [Full Text] [PDF]

				S. J. Ragg, S. Kaga, K. A. Berg, and A. Ochi The Mitogen-Activated Protein Kinase Pathway Inhibits Ceramide-Induced Terminal Differentiation of a Human Monoblastic Leukemia Cell Line, U937 J. Immunol., August 1, 1998; 161(3): 1390 - 1398. [Abstract] [Full Text] [PDF]

				X. Yang, M. O. Gold, D. N. Tang, D. E. Lewis, E. Aguilar-Cordova, A. P. Rice, and C. H. Herrmann TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines PNAS, November 11, 1997; 94(23): 12331 - 12336. [Abstract] [Full Text] [PDF]

				C. Asiedu, J. Biggs, and A. S. Kraft Complex Regulation of CDK2 During Phorbol Ester-Induced Hematopoietic Differentiation Blood, November 1, 1997; 90(9): 3430 - 3437. [Abstract] [Full Text] [PDF]

				M. C. Bosco, S. Rottschafer, L. S. Taylor, J. R. Ortaldo, D. L. Longo, and I. Espinoza-Delgado The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rgamma Chain Expression Blood, May 1, 1997; 89(9): 3402 - 3411. [Abstract] [Full Text] [PDF]

				M. R. Frey, M. L. Saxon, X. Zhao, A. Rollins, S. S. Evans, and J. D. Black Protein Kinase C Isozyme-mediated Cell Cycle Arrest Involves Induction of p21waf1/cip1 and p27kip1 and Hypophosphorylation of the Retinoblastoma Protein in Intestinal Epithelial Cells J. Biol. Chem., April 4, 1997; 272(14): 9424 - 9435. [Abstract] [Full Text] [PDF]